CORVUS PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.16 USD | +2.37% |
|
+4.85% | +22.73% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 160 | 99.9 | 112.2 | 39.57 | 86.31 | 135.1 | - | - |
| Enterprise Value (EV) 1 | 160 | 99.9 | 112.2 | 39.57 | 86.31 | 135.1 | 135.1 | 135.1 |
| P/E ratio | -3.42 x | -17.8 x | -2.34 x | -0.96 x | -3.14 x | -4.5 x | -3.96 x | -3.38 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | - | 20.1 x |
| EV / Revenue | - | - | - | - | - | - | - | 20.1 x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | -4.37 x | - | -3.06 x | -1.45 x | - | -5.87 x | -4.5 x | -2.87 x |
| FCF Yield | -22.9% | - | -32.7% | -69% | - | -17% | -22.2% | -34.8% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 29,405 | 28,062 | 46,548 | 46,554 | 49,039 | 62,551 | - | - |
| Reference price 2 | 5.440 | 3.560 | 2.410 | 0.8500 | 1.760 | 2.160 | 2.160 | 2.160 |
| Announcement Date | 3/5/20 | 3/25/21 | 3/10/22 | 3/28/23 | 3/19/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | 6.718 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -48.85 | -43.76 | -38.63 | -32.56 | -23.41 | -32.16 | -46.17 | -56.37 |
| Operating Margin | - | - | - | - | - | - | - | -839.16% |
| Earnings before Tax (EBT) 1 | -46.67 | -5.995 | -43.24 | -41.31 | -27.03 | -28.91 | -44.32 | -56.54 |
| Net income 1 | -46.67 | -5.995 | -43.24 | -41.31 | -27.03 | -30.32 | -45.74 | -55.65 |
| Net margin | - | - | - | - | - | - | - | -828.45% |
| EPS 2 | -1.590 | -0.2000 | -1.030 | -0.8900 | -0.5600 | -0.4800 | -0.5450 | -0.6400 |
| Free Cash Flow 1 | -36.58 | - | -36.72 | -27.29 | - | -23 | -30 | -47 |
| FCF margin | - | - | - | - | - | - | - | -699.67% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/5/20 | 3/25/21 | 3/10/22 | 3/28/23 | 3/19/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -6.81 | -7.413 | -7.013 | -12.47 | -5.666 | -6.574 | -5.622 | -5.56 | -5.651 | -6.253 | -7.502 | -8.718 | -9.697 | -10.7 | -11.1 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -9.236 | -8.297 | -8.363 | -14.83 | -9.816 | -7.873 | -6.503 | -6 | -6.653 | -5.701 | -6.968 | -7.495 | -8.569 | -10.3 | -10 |
| Net income 1 | -9.236 | -8.297 | -8.363 | -14.83 | -9.816 | -7.873 | -6.503 | -6 | -6.653 | -5.701 | -7.263 | -8.121 | -9.177 | -10.3 | -9.7 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.2000 | -0.1800 | -0.1800 | -0.3200 | -0.2100 | -0.1700 | -0.1400 | -0.1200 | -0.1400 | -0.1200 | -0.1150 | -0.1225 | -0.1300 | -0.1500 | -0.1500 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/10/22 | 5/5/22 | 8/8/22 | 11/3/22 | 3/28/23 | 5/8/23 | 8/8/23 | 11/7/23 | 3/19/24 | 5/6/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -36.6 | - | -36.7 | -27.3 | - | -23 | -30 | -47 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 0.03 | - | 0.01 | 0.27 | - | - | 1 | 1 |
| Capex / Sales | - | - | - | - | - | - | - | 14.89% |
| Announcement Date | 3/5/20 | 3/25/21 | 3/10/22 | 3/28/23 | 3/19/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.16
USD
Average target price
7.833
USD
Spread / Average Target
+262.65%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +22.73% | 135M | |
| +43.36% | 54.64B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +0.04% | 12.16B | |
| +25.12% | 12.21B | |
| +26.04% | 11.94B |
- Stock Market
- Equities
- CRVS Stock
- Financials Corvus Pharmaceuticals, Inc.
